secwatch.observer — SEC 8-K summary
======================================

Issuer:     Candel Therapeutics, Inc. (CADL)
CIK:        0001841387
Form:       8-K
Filed at:   2025-03-13T23:59:59+00:00
Accession:  0000950170-25-038757
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Candel Therapeutics reports positive phase 3 CAN-2409 data in prostate cancer; cash runway into Q1 2027
--------------------------------------------------------------------------------

- Positive phase 3 results for CAN-2409 in prostate cancer: 30% risk reduction, 80.4% pathological complete responses; BLA submission expected Q4 2026.
- Phase 2a pancreatic cancer: median OS 31.4 months (CAN-2409) vs 12.5 months (control); long-term survivors.
- Cash and cash equivalents $102.7M as of Dec 31, 2024; sufficient into Q1 2027.
- Net loss for full year 2024: $55.2M; R&D expenses decreased to $19.3M from $24.5M.
- Upcoming milestones: NSCLC final OS data Q1 2025; CAN-3110 data Q4 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1841387/000095017025038757/0000950170-25-038757-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1841387/000095017025038757/cadl-20250313.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-038757

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer